Pipeline of PD

This generated page lists source notes whose first nav_path entry is Pipeline of PD. It is a coverage index, not a full synthesis page.

sourcenav pathheadings
20240722_184327Pipeline of PD > aSyn - Antibody > aSyn - Small moleculesPasadena trial design (Part 1 / Part 2 / Part 3); mAbs summary; aSyn - Small molecules; Uncertain Spans
20240722_184330Pipeline of PD > aSyn - VaccineaSyn - Vaccine — NPT200-11 row tail (Neuropore), Anle138b / Ionis / PD1601 row tail, AC Immune PD01A (ACI-7104) and PD03A AFFiRiS row group (P2 VacSYn / NCT06015841, P1 MSA / NCT02270489, P1 NCT01568099 / sPD), AFF008 study series, CSF Oligo-aSyn / MDS-UPDRS III, SAD study MEDI1341 PK data; NPT200-11 / aS aggregation inhibitor (Neuropore, NCT02606682); AC Immune: PD01A (ACI-7104) and PD03A AFFiRiS; P2 VacSYn / NCT06015841; P1, MSA (ClinicalTrial.gov identifier: NCT02270489); …
20240722_184333Pipeline of PD > GTaSyn - Vaccine / GT Transition; SAD Study - PK Data To Date / MEDI1341; PD01A / Long-Term Follow-Up Notes; PD01A / GBA-PD Row; UB-312 / Vaxxinity; …
20240722_184337Pipeline of PDPipeline of PD — gene therapy and cell therapy (continued); Cell therapy; Inflammation; 기타 MOA들; Uncertain Spans
20240722_184351Pipeline of PD > 기타 MOA들기타 MOA들 (continued); Uncertain Spans
20240722_184447Pipeline of PD > GTAAV biodistribution evidence, ICM delivery comparison, and start of intra-parenchymal slide; NHP AAV9 biodistribution evidence (top of capture); Administration Via Intra-cisterna magna (ICM) Allows Early Intervention To PARK2 PD Patients Less Invasively; Intra-cisterna magna (ICM) delivery is tested in current clinical trials; Intra-Parenchymal Delivery; …
20240722_184516Pipeline of PD > GTSV Steps, Genetics Synapse, Imaging Synapse, and start of Readouts of Synapse; SV Steps; 3-1) clathrin-mediated pathway (major pathway); 3-2) kiss and run pathway; 3-3) several variations of bulk endocytosis such as ultrafast and activity-dependent bulk endocytosis; …